AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

NeVa ONE Registry Study

RecruitingNAAges 18 Years - anyAllVesalio
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

A prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Only subjects already treated with the NeVa thrombectomy devices can be considered for enrollment. 1. Age โ‰ฅ18 2. NIHSS score โ‰ฅ 6 3. Pre-stroke mRS score โ‰ค 1 4. Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA. 5. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well \[TLKW\]) 6. Imaging Inclusion Criteria: The patient should have confirmed LVO and salvageable penumbra. Any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines: * ASPECTS 6-10 if treatment started 0-6 hours from TLKW * ASPECTS 8-10 if treatment started 6-24 hours from TLKW * Ischemic core โ‰ค 50 cc 7. Subject or legal representative is able and willing to give informed consent within 72 hours after the intervention (may use independent physician consent in this timeframe and gain subject or legal representative consent later than 72 hours). Exclusion Criteria: 1. Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept). 2. Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration. 3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories 4. Cerebral vasculitis 5. History of severe allergy to contrast medium. 6. Known allergy to NeVa materials (nitinol, stainless steel) 7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis 8. Systemic infection 9. Significant mass effect with midline shift 10. Evidence of intracranial tumor (except small meningioma) 11. Inability to deploy NeVA device for at least one pass for any other reason 12. Life expectancy less than 6 months 13. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
๐Ÿ’Š

What it tests

  • NeVa Stent Retriever
๐Ÿ“

Where

3 sites
Hospital Espanol de Mendoza
Mendoza, Argentina
Niguarda Hospital
Milan, Italy
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy